Group 1 - The core viewpoint of the article is that Hanse Aitai-B (03378) has successfully completed its IPO with significant oversubscription, raising substantial capital for its product development [1][2]. - The company has raised HKD 1,472.9 billion in margin financing, with the public offering being oversubscribed by 2,511 times, indicating strong investor interest [1]. - Hanse Aitai plans to issue 18.32 million H-shares, with a public offering accounting for 10% of the total shares, and the share price set between HKD 28 to 32 [1]. Group 2 - The product pipeline includes one core product and nine other candidates, with three clinical-stage candidates targeting oncology, including the core product HX009 [2]. - HX009 is a bispecific antibody fusion protein targeting both CD47 and PD-1, leading in clinical trial progress among similar products globally [2]. - The company reported operating losses during the historical record period, with losses of RMB 85.16 million, RMB 117 million, and RMB 87.44 million for the fiscal years ending August 31, 2023, 2024, and 2025 respectively [2]. Group 3 - The company plans to allocate approximately 35% of the net proceeds from the global offering to the development of its core product HX009, 33% to its main products HX301 and HX044, and 17% to other important products [3]. - Additionally, about 5% of the proceeds will be used for commercialization and business development activities, while 10% will be allocated for working capital and other general corporate purposes [3].
新股消息 翰思艾泰-B(03378)招股结束 孖展认购额录得1472.9亿港元 超购2511倍